ClinicalTrials.gg
RecruitingNCT07045051Updated Jul 1, 2025

Glycemic/Insulinemic Effects of Fresh Mango as a Sugar Substitute in Realistic Breakfasts.

An interventional study of Low-Glycemic Breakfast Containing Oats and Mango and High-Glycemic Breakfast Containing Cereal and Mango in Healthy Participants, sponsored by Ball State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Ball State University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Large blood sugar and insulin increases after meals high in table sugar are related to risk for diabetes and heart disease. Additionally, large increases in blood sugar may also negatively impact vascular health. Previous research suggests that mango consumed in small quantities has blood sugar-lowering properties, but the evidence of this within larger, more realistic meals is limited. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to more favorable blood sugar, insulin, and vascular responses after eating breakfast meals. The investigators will compare the postprandial glycemic, insulinemic, and vascular response to low and high glycemic meals sweetened with either fresh mango or sucrose.

Read the detailed description

The investigators will recruit individuals with a BMI in the 18.5-35.0 kg/m2 range from the Ball State University campus and surrounding communities. Each participant will complete four meal trials in a randomized crossover design. At each meal trial, an intravenous catheter will be inserted and baseline blood sample collected. Brachial artery dilation will be measured using prior to the meal. Next, participants will consume one of four breakfast meals in a randomized crossover design: (1) cornflakes with 2% milk + fresh mango, (2) cornflakes with 2% milk + sucrose, (3) steel cut oats with water + fresh mango, and (4) steel cut oats with water + sucrose. Corn flakes based meals and oats based meals reflect high and low glycemic breakfasts, respectively. Within high and low glycemic meal conditions, total sugar from mango and sugar are matched, total energy is nearly identical (within 4 kcal), and macronutrients are matched.

After each meal, blood samples will be collected at the .5-, 1-, 2-, and 3-hour mark and brachial artery dilation (using the flow-mediated dilation technique) will be measured at 1-, 2-, and 3-hour marks. An acceptability survey (9-point hedonic scale) will be completed following the meal, and a satiety survey (the SLIM) will be filled out at baseline and .5-, 1-, 1.5-, 2-, 2.5-, and 3-hour mark. The investigators will measure metabolic markers (i.e., glucose, triglycerides, HDL-C) immediately after each sample collection using the Piccolo Xpress clinical chemical analyzer. Additional blood will be collected and stored as serum in order to measure insulin using commercially available ELISAs. Participants will complete a one-time DXA scan to measure body composition and bone density.

02

Conditions studied

  • Healthy Participants

Keywords

  • glycemia
  • insulinemia
  • fresh mango
  • vascular health
03

In context

Lead sponsor

Ball State University is the lead sponsor of 13 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 45 years.
  • between 18.5-35.0 kg/m2
  • Not pregnant (females only)
  • Not (females only).
  • Not been diagnosed with cardiovascular disease.
  • Not been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes)
  • Not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
  • Does not regularly take anti-inflammatory drugs (more than 2x week).
  • Does not use glucose-lowering drugs (e.g., metformin)
  • Does not use lipid-lowering drugs (e.g., statins)
  • Does not use tobacco products or any illicit drugs.
  • Does not have a pacemaker.
  • Can consume mango, wheat, gluten, and milk.
  • Can stay in a supine position in the dark for at least ten minutes.

Exclusion criteria

Exclusion Criteria:

  • Not between the ages of 18-45
  • \< 18.5 kg/m2 or >35.0 kg/m2
  • Pregnant (females only)
  • status (females only).
  • Been diagnosed with cardiovascular disease.
  • Been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes)
  • Been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
  • Regularly take anti-inflammatory drugs (more than 2x week).
  • Uses glucose-lowering drugs (e.g., metformin)
  • Uses lipid-lowering drugs (e.g., statins)
  • Uses tobacco products or any illicit drugs.
  • Have a pacemaker.
  • Allergic to mango, wheat, gluten, and/or milk.
  • Unable to lay in supine position in the dark for at least ten minutes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cereal Consumption with Mango

    During the Cereal and Mango arm, participants will consume a bowl of corn flakes with 2% milk sweetened with fresh mango.

    Other: High-Glycemic Breakfast Containing Cereal and Mango

  • Experimental
    Cereal Consumption with Table Sugar

    During the Cereal and Table Sugar arm, participants will consume a bowl of corn flakes with 2% milk sweetened with table sugar.

    Other: High-Glycemic Breakfast Containing Cereal and Table Sugar

  • Experimental
    Oat Consumption with Mango

    During the Oats and Mango Arm, participants will consume a bowl of oats prepared with water and sweetened with fresh mango.

    Other: Low-Glycemic Breakfast Containing Oats and Mango

  • Experimental
    Oat Consumption with Table Sugar

    During the Oat and Table Sugar arm, participants will consume a bowl of oats prepared with water and sweetened with table sugar.

    Other: Low-Glycemic Breakfast Containing Oats and Table Sugar

Interventions

  • OtherLow-Glycemic Breakfast Containing Oats and Mango

    Low-glycemic breakfast of 80 grams of oats prepared with 473mL water and sweetened with 146 grams of mango.

  • OtherHigh-Glycemic Breakfast Containing Cereal and Mango

    High-glycemic breakfast of 84 grams of corn flakes prepared with 355mL of 2% milk and sweetened with 262 grams of mango.

  • OtherLow-Glycemic Breakfast Containing Oats and Table Sugar

    Low-glycemic breakfast of 80 grams of oats prepared with 473mL of water and sweetened with 20 grams of table sugar.

  • OtherHigh-Glycemic Breakfast Containing Cereal and Table Sugar

    High-glycemic breakfast of 84 grams of corn flakes prepared with 355mL of 2% milk and sweetened with 36 grams of table sugar.

06

What researchers measure

Primary outcomes

  1. Glucose

    The investigators will measure glucose at baseline and .5-, 1-, 2-, and 3-hours after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  2. Insulin

    The investigators will measure insulin at baseline and .5- 1-, 2-, and 3-hours after each meal containing. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  3. Flow-mediated Dilation

    The investigators will measure FMD at baseline and 1-, 2-, and 3-hours after the meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1 year.

Secondary outcomes

  1. HDL-C

    The investigators will measure HDL-C at baseline and .5-, 1-, 2-, and 3-hours after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1 year.

  2. Triglycerides

    The investigators will measure triglycerides at baseline and .5-, 1-, 2-, and 3-hours after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1 year.

  3. Acceptability

    The investigators will measure acceptability of each meal with a survey at each study visit once post-meal.

    Time frame: Through study completion, up to 1 year.

  4. Satiety

    The investigators will measure satiety through a survey at baseline and at .5-, 1-, 1.5-, 2-, 2.5-, and 3-hours after the meal.

    Time frame: Through study completion, up to 1 year.

Other outcomes

  1. Body Composition

    The investigators will measure body composition using bioelectrical impedance (InBody).

    Time frame: Through study completion, up to 1 year.

  2. Systolic and Diastolic Pressure

    The investigators will measure blood pressure using an automated cuff (Omron).

    Time frame: Through study completion, up to 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 1, 2025
StartActual
Mar 26, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07045051
Lead sponsor
Ball State University
Collaborators
National Mango Board
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
Mar 26, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jul 1, 2025

Study contacts

Bryant Keirns, PhD
Contact
bryant.keirns@bsu.edu
765-285-8356
Bryant Keirns, PhD
principal investigator · Ball State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion